Dr. KinyasHair Clinic · IstanbulLibrary ←
Science and Research Centre / Hair Loss and Treatments

Dr. Kinyas Hair Clinic · Science and Research Centre

Telogen Effluvium: Understand the Cause of Sudden Diffuse Shedding

More hairs in the shower or comb do not mean permanent baldness. Telogen effluvium is diffuse shedding related to cycle changes. First understand the cause and possible coexisting loss, rather than rushing to a procedure.

Why can shedding begin months after a trigger?

Hair cycles through growth and rest. After illness, childbirth, surgery, major weight loss or other triggers, shedding may appear months later rather than immediately. Describe preceding months as well as recent weeks. [1], [2]

No identifiable trigger does not make symptoms unimportant. Medicines, nutrition and health require assessment together. Discuss suspected drugs with the prescriber rather than stopping yourself. [1], [2]

Distinguishing telogen effluvium and AGA

Telogen effluvium often presents diffusely; AGA involves miniaturisation and patterned thinning. They can coexist. Counts or one image may not distinguish them. [2], [3]

Examination and, if needed, trichoscopy assess distribution, shaft variation and skin. Biopsy is not universal; diagnostic uncertainty and justification guide it. Histology should not become a threshold independent of history. [3], [4]

Does everyone need the same tests?

Tests follow history and examination. Suspected disease, deficiency, hormonal issues or infection may warrant targeted tests. Broad panels for everyone or one ideal hair value are inappropriate. [4]

Bring prior tests, medicines/supplements and photographs. Mention biotin because it can interfere with assays. Association between a value and shedding does not prove identical responses to supplementation. [4], [5]

When might recovery occur?

Acute shedding often settles after correcting the trigger, while visible density and length take longer. Common month ranges are not personal deadlines. Persistent or increasing loss needs reassessment. [1], [2]

Planned comparable photographs can be more useful than daily counting. Reduced shedding and restored length do not occur simultaneously. Share anxiety too; the monitoring plan should be understandable. [1], [2] (photograph intervals: clinical follow-up recommendation)

Does everyone need drugs, PRP or vitamins?

Finding and correcting triggers can be central in acute cases. Some need additional treatment, but the diagnosis does not mandate one drug or injection package for all. Cause and persistence require review. [1], [6]

The accessible publisher abstract of a 2026 expert consensus highlights limited high-quality chronic-effluvium treatment research. Individual clinical options are not equivalent to strong randomised evidence or universal care. Full recommendation tables were not read, so no dose or routine schedule was derived. [6]

Which findings should not wait?

New patches, marked redness, scaling, pus or increasing pain warrant earlier examination. They may suggest something beyond simple telogen shedding; do not self-diagnose here. Report significant general symptoms too. [3], [4] (clinical assessment recommendation)

Post-transplant shaft shedding alone is not graft loss. Bleeding, tissue fragments, new pain or suspected infection need your care team’s assessment. See the postoperative shedding article; not all loss shares one mechanism.

Why avoid rushing the transplant decision?

With temporary or unexplained diffuse shedding, clarify what surgery would solve first. It redistributes follicles rather than treating cycle triggers. Coexisting AGA can inform combined medical/surgical planning. [1], [3] (clinical adaptation for surgical decisions)

Discuss diagnosis, goals and follow-up sequence with Dr. Kinyas. Assessment or observation first does not mean no solution; it clarifies the basis of a durable plan. This page declares neither universal suitability nor exclusion.

References and access limitations

This article is based on a targeted review of sources; it is not an original systematic review.

  1. British Association of Dermatologists. Telogen effluvium patient information leaflet. October 2025.

    Professional patient information. Triggers, assessment and treatment text accessed. Timings are not individual guarantees; reported proportions not used as diagnostic cut-offs.

  2. American Academy of Dermatology. Do you have hair loss or hair shedding?

    Professional patient information. Loss/shedding and delayed onset/follow-up sections accessed. Not an efficacy trial or universal recovery promise.

  3. Alopecia: Histologic Diagnosis of Nonscarring Alopecias. Actas Dermo-Sifiliográficas. 2015. DOI: 10.1016/j.adengl.2015.01.001.

    Diagnostic histopathology review. Not all proportions or treatment algorithms verified; biopsy not presented as mandatory.

  4. American Academy of Dermatology. Hair loss: Diagnosis and treatment.

    Professional diagnosis information. History/examination and indicated blood tests/biopsy accessed. No fixed panel or personal diagnosis derived.

  5. FDA. Biotin Interference with Troponin Lab Tests.

    Laboratory safety information; official text accessed in prior supplement review. Assay/manufacturer differences; no fixed stopping interval.

  6. Expert consensus recommendations on appropriate treatment for telogen effluvium. JDPA. 2026;20(3):8–13. DOI: 10.1097/jdpa.0000000000000114.

    Expert consensus; accessible publisher abstract. Professional affiliation verified; full text inaccessible. No efficacy or doses inferred from title. Recommendation tables/conflicts remain unreviewed.

← Back to section
WhatsApp
DR. KINYAS HAIR CLINIC

Quick Contact

Leave your details and we will contact you through your preferred channel.

How should we contact you?

Dr. Kinyas Hair Clinic uses your details to respond to your request and contact you.